Evaluation of Regional Lung Deposition of Inhaled Saline Using the tPAD Device

Exclusion Criteria

• •1. Subjects who have evidence of an upper or lower respiratory infection or clinically significant illness at entry or within 14 days of the start of dosing.
• •2. Subjects with lung diseases as defined by a FEV1 \<80% or a FEV1/FVC \<70%
• •3. Subjects on inhaled medications, such as short or long acting bronchodilators or inhaled corticosteroids, will be excluded.
• •4. Subjects with a history of allergy or intolerance to albuterol or hypertonic saline.
• •5. Subjects with active chronic or acute rhinosinusitis or other nasal or sinus abnormality or disease.
• •6. Subjects who have a present history of any clinically significant neurologic, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological disorder or disease, substance abuse, or any other major disorder or disease.
• •7. Subjects who have had radiation exposure within the past year that would cause them to exceed Federal Regulations of 15 Rem annually by participating in this study. The study team will determine this.
• •8. Subjects with a history of smoking within the last 3 months.
• •9. Subjects with a positive pregnancy test or who are pregnant or are nursing.
• •10. Subjects who, in the opinion of the Principal Investigator, should not participate in the study.
• •11. Subjects with a BMI \>30 kg/m2
• •12. Subjects who are taller than Height \>6'2"
• •13. Subjects who have facial hair that they are not willing to shave